HOXDeRNA promoted astrocyte transformation by releasing PRC2 repression at glioma transcription factor promoters (SOX2, OLIG2) and activating super enhancers, leading to oncogene upregulation [17]. The gene discussed is OLIG2; the disease is central nervous system cancer.